A new treatment for airway diseases like asthma and COPD
A New Small-Molecule Kinase Inhibitor for Airway Disease
['FUNDING_OTHER'] · NUPEAK THERAPEUTICS, INC. · NIH-10805979
This study is working on a new medication that could help people with asthma and COPD by targeting a specific protein that causes inflammation and mucus buildup in the airways, aiming to create better treatment options for those who struggle with these breathing issues.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NUPEAK THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10805979 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel small-molecule kinase inhibitor aimed at treating respiratory airway diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). The approach involves targeting a specific protein, MAPK13, which plays a crucial role in airway inflammation and mucus production. By utilizing advanced drug design techniques, the researchers aim to create a compound that can effectively inhibit this protein, potentially leading to improved treatment options for patients suffering from these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with asthma, COPD, or long-term effects of COVID-19 who are seeking new treatment options.
Not a fit: Patients with airway diseases not related to asthma, COPD, or long-term COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients with asthma and COPD, potentially reducing symptoms and improving quality of life.
How similar studies have performed: While targeting MAPK13 is a relatively novel approach, previous research has shown promise in developing kinase inhibitors for similar conditions, indicating potential for success.
Where this research is happening
SAINT LOUIS, UNITED STATES
- NUPEAK THERAPEUTICS, INC. — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BROSCHAT, KAY O — NUPEAK THERAPEUTICS, INC.
- Study coordinator: BROSCHAT, KAY O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway Disease